255 related articles for article (PubMed ID: 33963012)
21. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy.
Miyashita M; Sasano H; Tamaki K; Chan M; Hirakawa H; Suzuki A; Tada H; Watanabe G; Nemoto N; Nakagawa S; Ishida T; Ohuchi N
Breast Cancer Res Treat; 2014 Dec; 148(3):525-34. PubMed ID: 25395319
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L
Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815
[TBL] [Abstract][Full Text] [Related]
23. WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial.
Hofmann D; Nitz U; Gluz O; Kates RE; Schinkoethe T; Staib P; Harbeck N
Trials; 2013 Aug; 14():261. PubMed ID: 23958221
[TBL] [Abstract][Full Text] [Related]
24. Functional CD3
Lv S; Wang S; Qiao G; Wang X; Zhou X; Yan F; Li Y; Wang S; Morse MA; Hobeika A; Ren J; Lyerly HK
Clin Breast Cancer; 2019 Oct; 19(5):e617-e623. PubMed ID: 31101455
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C
Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer.
Ahmed FS; Gaule P; McGuire J; Patel K; Blenman K; Pusztai L; Rimm DL
Clin Cancer Res; 2020 Oct; 26(20):5456-5461. PubMed ID: 32709714
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors.
Baram T; Erlichman N; Dadiani M; Balint-Lahat N; Pavlovski A; Meshel T; Morzaev-Sulzbach D; Gal-Yam EN; Barshack I; Ben-Baruch A
Cells; 2021 Jun; 10(6):. PubMed ID: 34201054
[TBL] [Abstract][Full Text] [Related]
29. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L
Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781
[TBL] [Abstract][Full Text] [Related]
30. Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer.
Ansari RE; Craze ML; Althobiti M; Alfarsi L; Ellis IO; Rakha EA; Green AR
Br J Cancer; 2020 Jan; 122(1):94-101. PubMed ID: 31819174
[TBL] [Abstract][Full Text] [Related]
31. Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer.
Leon-Ferre RA; Whitaker KR; Suman VJ; Hoskin T; Giridhar KV; Moore RM; Al-Jarrad A; McLaughlin SA; Northfelt DW; Hunt KN; Conners AL; Moyer A; Carter JM; Kalari K; Weinshilboum R; Wang L; Ingle JN; Knutson KL; Ansell SM; Boughey JC; Goetz MP; Villasboas JC
Breast Cancer Res; 2024 Jun; 26(1):97. PubMed ID: 38858721
[TBL] [Abstract][Full Text] [Related]
32. Predictive markers for pathological complete response after neo-adjuvant chemotherapy in triple-negative breast cancer.
Van Bockstal MR; Noel F; Guiot Y; Duhoux FP; Mazzeo F; Van Marcke C; Fellah L; Ledoux B; Berlière M; Galant C
Ann Diagn Pathol; 2020 Dec; 49():151634. PubMed ID: 32987254
[TBL] [Abstract][Full Text] [Related]
33. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma.
Böhm S; Montfort A; Pearce OM; Topping J; Chakravarty P; Everitt GL; Clear A; McDermott JR; Ennis D; Dowe T; Fitzpatrick A; Brockbank EC; Lawrence AC; Jeyarajah A; Faruqi AZ; McNeish IA; Singh N; Lockley M; Balkwill FR
Clin Cancer Res; 2016 Jun; 22(12):3025-36. PubMed ID: 27306793
[TBL] [Abstract][Full Text] [Related]
35. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
Wang K; Shen T; Siegal GP; Wei S
Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
[TBL] [Abstract][Full Text] [Related]
36. Triple negative breast cancer - prognostic role of immune-related factors: a systematic review.
Stovgaard ES; Nielsen D; Hogdall E; Balslev E
Acta Oncol; 2018 Jan; 57(1):74-82. PubMed ID: 29168430
[TBL] [Abstract][Full Text] [Related]
37. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
38. Programmed cell death protein 1 is a marker for neoadjuvant chemotherapy response in triple-negative breast cancer.
Gaui MFD; Amendola LC; Quintella DC; Canedo N; Bonomo A
Rev Assoc Med Bras (1992); 2023; 69(9):e20230276. PubMed ID: 37729362
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
Lee J; Kim DM; Lee A
Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
[TBL] [Abstract][Full Text] [Related]
40. The Prognostic Value of CD39 as a Marker of Tumor-Specific T Cells in Triple-Negative Breast Cancer in Asian Women.
Meng J; Tan JYT; Joseph CR; Ye J; Lim JCT; Goh D; Xue Y; Lim X; Koh VCY; Wee F; Tay TKY; Chan JY; Ng CCY; Iqbal J; Lau MC; Lim HE; Toh HC; Teh BT; Dent RA; Tan PH; Yeong JPS
Lab Invest; 2024 Mar; 104(3):100303. PubMed ID: 38103870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
